Developing a new class of engineered live bacterial therapeutics to treat human diseases

por Mark R. Charbonneau, Vincent M. Isabella, Ning Li, Caroline B. Kurtz
Publicado 2020

Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria

por Mark R. Charbonneau, William S. Denney, Nicholas G. Horvath, Pasquale Cantarella, Mary J. Castillo, Marja K. Puurunen, Aoife M. Brennan
Publicado 2021

Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip

por M. Tyler Nelson, Mark R. Charbonneau, Heidi G. Coia, Mary J. Castillo, Corey Holt, Eric S. Greenwood, Peter J. Robinson, Elaine A. Merrill, David Lubkowicz, Camilla A. Mauzy
Publicado 2021